Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs

The Biopharmaceutics Classification System (BCS) categorizes drugs into one of four biopharmaceutical classes according to their water solubility and membrane permeability characteristics and broadly allows the prediction of the rate-limiting step in the intestinal absorption process following oral administration. Since its introduction in 1995, the BCS has generated remarkable impact on the global pharmaceutical sciences arena, in drug discovery, development, and regulation, and extensive validation/discussion/extension of the BCS is continuously published in the literature. The BCS has been effectively implanted by drug regulatory agencies around the world in setting bioavailability/bioequivalence standards for immediate-release (IR) oral drug product approval. In this review, we describe the BCS scientific framework and impact on regulatory practice of oral drug products and review the provisional BCS classification of the top drugs on the global market. The Biopharmaceutical Drug Disposition Classification System and its association with the BCS are discussed as well. One notable finding of the provisional BCS classification is that the clinical performance of the majority of approved IR oral drug products essential for human health can be assured with an in vitro dissolution test, rather than empirical in vivo human studies.

[1]  Gordon L. Amidon,et al.  Estimating the Fraction Dose Absorbed from Suspensions of Poorly Soluble Compounds in Humans: A Mathematical Model , 1993, Pharmaceutical Research.

[2]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). , 2006, Journal of pharmaceutical sciences.

[3]  Jack A. Cook,et al.  Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond , 2008, The AAPS Journal.

[4]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. , 2006, Journal of pharmaceutical sciences.

[5]  Anders Karlén,et al.  Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. , 2003, Journal of molecular graphics & modelling.

[6]  S. Kopp PROPOSAL TO WAIVE IN VIVO BIOEQUIVALENCE REQUIREMENTS FOR THE WHO MODEL LIST OF ESSENTIAL MEDICINES IMMEDIATE RELEASE, SOLID ORAL DOSAGE FORMS , 2005 .

[7]  Hans Lennernäs,et al.  The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension , 2005, The Journal of pharmacy and pharmacology.

[8]  A. Hoffman,et al.  Enhanced Gastrointestinal Absorption of Lipophilic Drugs , 2006 .

[9]  M. Sherry Ku,et al.  Use of the Biopharmaceutical Classification System in Early Drug Development , 2008, The AAPS Journal.

[10]  A. Dahan,et al.  Food–drug interaction: grapefruit juice augments drug bioavailability—mechanism, extent and relevance , 2004, European Journal of Clinical Nutrition.

[11]  G L Amidon,et al.  Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.

[12]  Leslie Z Benet,et al.  Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. , 2008, Advanced drug delivery reviews.

[13]  M. Bermejo,et al.  Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  B. Schug,et al.  The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  Lawrence X. Yu,et al.  A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. , 2006, Molecular pharmaceutics.

[16]  Vinod P. Shah,et al.  The Use of BDDCS in Classifying the Permeability of Marketed Drugs , 2008, Pharmaceutical Research.

[17]  R. Löbenberg,et al.  Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards , 2000 .

[18]  Lawrence X. Yu,et al.  The use of drug metabolism for prediction of intestinal permeability (dagger). , 2009, Molecular pharmaceutics.

[19]  Nipa Shah,et al.  Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. , 2009, Molecular pharmaceutics.

[20]  H Lennernäs,et al.  Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.

[21]  Lawrence X. Yu,et al.  Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. , 2005, Molecular pharmaceutics.

[22]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[23]  G. Amidon,et al.  The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. , 2006, Molecular pharmaceutics.

[24]  G. Amidon,et al.  Gastrointestinal Dissolution and Absorption of Class II Drugs , 2008 .

[25]  G. Amidon,et al.  The H2 Receptor Antagonist Nizatidine is a P-Glycoprotein Substrate: Characterization of its Intestinal Epithelial Cell Efflux Transport , 2009, The AAPS Journal.

[26]  J. Polli In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms , 2008, The AAPS Journal.

[27]  Lawrence X. Yu,et al.  The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. , 2004, Molecular pharmaceutics.

[28]  S. Yamashita,et al.  Analysis of risk factors in human bioequivalence study that incur bioinequivalence of oral drug products. , 2009, Molecular pharmaceutics.

[29]  Mei-Ling Chen,et al.  Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. , 2004, Journal of pharmaceutical sciences.

[30]  Vinod P. Shah,et al.  Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.

[31]  G. Amidon,et al.  Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[32]  Lawrence X. Yu,et al.  In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. , 2004, Current opinion in drug discovery & development.

[33]  G. Amidon,et al.  Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. , 2004, Molecular pharmaceutics.

[34]  H Lennernäs,et al.  Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.

[35]  John M Hilfinger BCS in drug discovery, development, and regulation. , 2009, Molecular pharmaceutics.

[36]  W. Addicks,et al.  Application of the Biopharmaceutical Classification System in Clinical Drug Development—An Industrial View , 2008, The AAPS Journal.

[37]  J. Kuhlmann,et al.  Guidances related to bioavailability and bioequivalence: European industry perspective , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[38]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: amitriptyline hydrochloride. , 2006, Journal of pharmaceutical sciences.

[39]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[40]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[41]  Han van de Waterbeemd,et al.  Drug bioavailability : estimation of solubility, permeability, absorption and bioavailability , 2003 .

[42]  Jennifer B Dressman,et al.  Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[43]  L. Benet,et al.  Net Secretion of Furosemide Is Subject to Indomethacin Inhibition, as Observed in Caco-2 Monolayers and Excised Rat Jejunum , 1999, Pharmaceutical Research.

[44]  S. Stavchansky Scientific Perspectives on Extending the Provision for Waivers of In vivo Bioavailability and Bioequivalence Studies for Drug Products Containing High Solubility-Low Permeability Drugs (BCS-Class 3) , 2008, The AAPS Journal.

[45]  Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I). , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  Jelena Parojcić,et al.  Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. , 2009, Molecular pharmaceutics.

[47]  Lawrence X. Yu,et al.  Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. , 2007, Molecular pharmaceutics.

[48]  J. Proudfoot,et al.  Tetrazole compounds: the effect of structure and pH on Caco-2 cell permeability. , 2006, Journal of pharmaceutical sciences.

[49]  Jennifer B Dressman,et al.  Feasibility of Biowaiver Extension to Biopharmaceutics Classification System Class III Drug Products , 2006, Clinical Pharmacokinetics.

[50]  B. W. Barry,et al.  Enhancement in Drug Delivery , 2006 .

[51]  Lawrence X. Yu,et al.  Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.